JP2012526992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526992A5 JP2012526992A5 JP2012511029A JP2012511029A JP2012526992A5 JP 2012526992 A5 JP2012526992 A5 JP 2012526992A5 JP 2012511029 A JP2012511029 A JP 2012511029A JP 2012511029 A JP2012511029 A JP 2012511029A JP 2012526992 A5 JP2012526992 A5 JP 2012526992A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- activation
- level
- cell
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 56
- 210000004027 cell Anatomy 0.000 claims 43
- 230000004913 activation Effects 0.000 claims 38
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 33
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000000284 extract Substances 0.000 claims 16
- 230000003321 amplification Effects 0.000 claims 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims 15
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 12
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 12
- 108020003175 receptors Proteins 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 239000000833 heterodimer Substances 0.000 claims 6
- 239000011324 bead Substances 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 102000003992 Peroxidases Human genes 0.000 claims 4
- 108010090804 Streptavidin Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 4
- 102000038030 PI3Ks Human genes 0.000 claims 3
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 239000011616 biotin Substances 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 3
- 239000007800 oxidant agent Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- VZWXNOBHWODXCW-ZOBUZTSGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-(4-hydroxyphenyl)ethyl]pentanamide Chemical group C1=CC(O)=CC=C1CCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 VZWXNOBHWODXCW-ZOBUZTSGSA-N 0.000 claims 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108010015776 Glucose oxidase Proteins 0.000 claims 2
- 239000004366 Glucose oxidase Substances 0.000 claims 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 230000005465 channeling Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 229940116332 glucose oxidase Drugs 0.000 claims 2
- 235000019420 glucose oxidase Nutrition 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical group CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 1
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 claims 1
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 1
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 claims 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000012916 chromogenic reagent Substances 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000123 paper Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17845809P | 2009-05-14 | 2009-05-14 | |
| US61/178,458 | 2009-05-14 | ||
| US18078709P | 2009-05-22 | 2009-05-22 | |
| US61/180,787 | 2009-05-22 | ||
| US18724609P | 2009-06-15 | 2009-06-15 | |
| US61/187,246 | 2009-06-15 | ||
| US22852209P | 2009-07-24 | 2009-07-24 | |
| US61/228,522 | 2009-07-24 | ||
| US23564609P | 2009-08-20 | 2009-08-20 | |
| US61/235,646 | 2009-08-20 | ||
| US24180409P | 2009-09-11 | 2009-09-11 | |
| US61/241,804 | 2009-09-11 | ||
| US26285609P | 2009-11-19 | 2009-11-19 | |
| US61/262,856 | 2009-11-19 | ||
| US26522709P | 2009-11-30 | 2009-11-30 | |
| US61/265,227 | 2009-11-30 | ||
| PCT/US2010/034814 WO2010132723A1 (en) | 2009-05-14 | 2010-05-13 | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526992A JP2012526992A (ja) | 2012-11-01 |
| JP2012526992A5 true JP2012526992A5 (enExample) | 2013-06-27 |
| JP5718319B2 JP5718319B2 (ja) | 2015-05-13 |
Family
ID=42315848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511029A Active JP5718319B2 (ja) | 2009-05-14 | 2010-05-13 | Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9726669B2 (enExample) |
| EP (1) | EP2430443B1 (enExample) |
| JP (1) | JP5718319B2 (enExample) |
| AU (1) | AU2010248884B2 (enExample) |
| CA (1) | CA2761777A1 (enExample) |
| NZ (2) | NZ596468A (enExample) |
| WO (1) | WO2010132723A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120295259A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
| US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| RU2558931C2 (ru) | 2010-01-12 | 2015-08-10 | Нестек С.А. | Способы предсказания ответа трижды негативного рака молочной железы на терапию |
| SG191230A1 (en) | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| MX343327B (es) | 2011-02-17 | 2016-11-01 | Nestec Sa | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. |
| BR112013020992A2 (pt) | 2011-02-17 | 2016-10-11 | Nestec Sa | aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração |
| EP2681552A2 (en) | 2011-03-02 | 2014-01-08 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
| KR20140020318A (ko) | 2011-04-04 | 2014-02-18 | 네스텍 소시에테아노님 | 위암 환자의 생존률 예측 및 개선 방법 |
| CA3295783A1 (en) | 2011-05-10 | 2026-03-02 | Prometheus Laboratories, Inc. | Methods of disease activity profiling for personalized therapy management |
| WO2012154935A1 (en) * | 2011-05-12 | 2012-11-15 | Eisai R&D Management Co., Ltd. | Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
| EP2788752B1 (en) | 2011-12-05 | 2018-10-03 | Pierian Holdings, Inc. | Method of therapy selection for patients with lung cancer |
| EP2605014A1 (en) * | 2011-12-16 | 2013-06-19 | Merck Patent GmbH | General strategy for antibody library screening |
| US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
| EP2863920B1 (en) | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
| ES2638971T3 (es) | 2012-10-05 | 2017-10-24 | Nestec S.A. | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| US20140221368A1 (en) * | 2013-02-01 | 2014-08-07 | Meso Scale Technologies, Llc | Biomarkers of therapeutic responsiveness |
| HK1218939A1 (zh) | 2013-02-05 | 2017-03-17 | Nestec S.A. | 用於非小细胞肺癌疗法的药物选择 |
| EP2954328A1 (en) | 2013-02-05 | 2015-12-16 | Nestec S.A. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| WO2014122600A1 (en) | 2013-02-05 | 2014-08-14 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
| JP6202362B2 (ja) * | 2013-03-04 | 2017-09-27 | 国立大学法人北海道大学 | 乳癌乳房温存療法後の局所再発リスクの予測に用いるための診断薬並びに予測方法 |
| EP3373010A1 (en) | 2013-05-21 | 2018-09-12 | Pierian Holdings, Inc. | Method for selecting a therapy for the treatment of colorectal cancer patients |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| WO2015028974A2 (en) | 2013-08-30 | 2015-03-05 | Nestec S.A. | Polyp recurrence |
| AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| WO2015083085A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Signaling pathways in tissues from inflammatory bowel disease patients |
| WO2015089380A2 (en) | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
| JP6666852B2 (ja) * | 2014-01-16 | 2020-03-18 | イルミナ インコーポレイテッド | 前立腺がん再発の予後に関する遺伝子発現パネル |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| KR101527797B1 (ko) | 2014-06-03 | 2015-06-15 | 한국과학기술원 | 신호전달경로의 활성화 상태 분석방법 및 이를 이용한 개인 맞춤형 치료제의 선정방법 |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| EP3699589A1 (en) * | 2014-12-12 | 2020-08-26 | Celcuity Inc. | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients |
| WO2016115105A1 (en) | 2015-01-12 | 2016-07-21 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| JP2015127711A (ja) * | 2015-02-10 | 2015-07-09 | 公立大学法人横浜市立大学 | 初期乳癌の検出方法 |
| CN104762264A (zh) * | 2015-04-20 | 2015-07-08 | 安徽安科生物工程（集团）股份有限公司 | 曲妥珠单抗耐药的人乳腺癌细胞株及其制备方法和应用 |
| CN109789204A (zh) * | 2016-05-31 | 2019-05-21 | 雀巢产品技术援助有限公司 | 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| EP3879269A3 (en) | 2017-03-20 | 2021-11-17 | Celcuity Inc. | Methods of measuring signaling pathway activity for selection of therapeutic agents |
| KR20200009095A (ko) | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | 크론병 환자에서 점막 치유를 평가하는 방법 |
| WO2019126168A1 (en) * | 2017-12-21 | 2019-06-27 | Proplex Technologies, LLC | Sensitive detection of g-protein coupled receptor-associated sorting protein 1 (gasp-1). gasp-1 microvesicles, and gasp-1 exosomes |
| WO2021108043A1 (en) | 2019-11-27 | 2021-06-03 | University Of Cincinnati | Assessing treatment response with estimated number of tumor cells |
| CN119614505B (zh) * | 2023-09-12 | 2025-12-05 | 珠海圣美生物诊断技术有限公司 | 稀有细胞捕获试剂组合及方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US6541214B1 (en) | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US7695926B2 (en) | 2001-07-10 | 2010-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting receptor-ligand interactions in single cells |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| WO2004000102A2 (en) | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| ATE442589T1 (de) | 2002-07-25 | 2009-09-15 | Aclara Biosciences Inc | Nachweis der rezeptoroligomerisierung |
| BRPI0408928A (pt) | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
| US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| US20100291594A1 (en) | 2003-07-17 | 2010-11-18 | Laboratory Corporation Of America Holdings | ErbB Surface Receptor Complexes as Biomarkers |
| WO2005011607A2 (en) | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| WO2005037071A2 (en) * | 2003-10-14 | 2005-04-28 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| JP5422120B2 (ja) | 2004-05-27 | 2014-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法 |
| WO2006044748A2 (en) | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
| CN104198705B (zh) * | 2006-09-21 | 2017-06-09 | 雀巢产品技术援助有限公司 | 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列 |
| WO2008109332A2 (en) | 2007-03-01 | 2008-09-12 | Targeted Molecular Diagnostics, Llc | Methods and compositions for determining the efficacy of breast cancer therapeutics |
| WO2008127707A1 (en) | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
| US20090017050A1 (en) | 2007-07-13 | 2009-01-15 | Ventana Medical Systems, Inc. | Egfr antigen-binding molecules and uses thereof |
| NZ582618A (en) * | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| AU2008317404B2 (en) | 2007-10-19 | 2014-12-18 | Cell Signaling Technology, Inc. | Cancer classification and methods of use |
| WO2009086197A1 (en) | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
| ES2553390T3 (es) * | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| EP2438442B1 (en) * | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| BRPI1007321A2 (en) | 2009-01-15 | 2018-07-10 | Laboratory Corporation Of America Holdings | methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody. |
| US20100332417A1 (en) | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| EP2473854B1 (en) | 2009-06-23 | 2017-08-23 | Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud | Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer |
| WO2011031982A1 (en) | 2009-09-10 | 2011-03-17 | Myriad Genetics, Inc. | Methods and compositions for predicting cancer therapy response |
| EP2330131B1 (en) | 2009-12-07 | 2014-10-08 | Fundació Privada Institució Catalana De Recerca I Estudis Avancats | Antibodies against HER2 truncated variant CTF-611 |
-
2010
- 2010-05-13 NZ NZ596468A patent/NZ596468A/xx not_active IP Right Cessation
- 2010-05-13 WO PCT/US2010/034814 patent/WO2010132723A1/en not_active Ceased
- 2010-05-13 NZ NZ616755A patent/NZ616755A/en not_active IP Right Cessation
- 2010-05-13 CA CA2761777A patent/CA2761777A1/en not_active Abandoned
- 2010-05-13 EP EP10720095.8A patent/EP2430443B1/en active Active
- 2010-05-13 JP JP2012511029A patent/JP5718319B2/ja active Active
- 2010-05-13 AU AU2010248884A patent/AU2010248884B2/en not_active Ceased
- 2010-08-10 US US12/854,144 patent/US9726669B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014525585A5 (enExample) | ||
| US7648828B2 (en) | Methods for detecting receptor complexes comprising PI3K | |
| Carrasco-Triguero et al. | Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine | |
| RU2012134390A (ru) | Способы предсказания ответа трижды негативного рака молочной железы на терапию | |
| JP2012533738A5 (enExample) | ||
| EP1613205B1 (en) | Erbb surface receptor complexes as biomarkers | |
| Özkan et al. | Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. | |
| JP2011514522A5 (enExample) | ||
| US20090111127A1 (en) | Surface Receptor Complexes as Biomarkers | |
| Agnolon et al. | ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab | |
| NZ596468A (en) | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy | |
| US20100291594A1 (en) | ErbB Surface Receptor Complexes as Biomarkers | |
| Smith et al. | Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts | |
| Baiocchi et al. | ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery | |
| Plucinski et al. | Malaria surveys using rapid diagnostic tests and validation of results using post hoc quantification of Plasmodium falciparum histidine-rich protein 2 | |
| Ho-Pun-Cheung et al. | Quantification of HER expression and dimerization in patients’ tumor samples using time-resolved Förster resonance energy transfer | |
| Carneiro et al. | based ELISA for fast CA 15–3 detection in point-of-care | |
| Oldak et al. | Two SPRi biosensors for the determination of cathepsin S in blood plasma | |
| Fazekas et al. | Two‐sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy | |
| TWI480553B (zh) | 糖化血紅素之偵測方法 | |
| Chen et al. | Development of an Ultrasensitive Monoclonal Antibody-Based Time-Resolved Fluorescence Immunochromatographic Assay for Mebendazole Detection | |
| US20230204578A1 (en) | Receptor tyrosine kinase biomarkers | |
| US10502746B2 (en) | Specific detection of rat antibodies in mouse serum | |
| JP6488236B2 (ja) | 可溶型線維芽細胞増殖因子受容体の高感度多重イムノアッセイ | |
| WO2014140554A1 (en) | Methods for detecting molecules in a sample |